You are here: Industry Insights > Thrombocytopenia

News List

Sobi launches thrombocytopenia drug Doptelet in EU pharmatimes
November 06, 2020
Sobi (Swedish Orphan Biovitrum) has launched Doptelet (avatrombopag) in Europe, which is approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD).
Thrombocytopenia patients set to get Mulpleo after UK launch pharmatimes
March 13, 2020
Shionogi & Co. has launched Mulpleo (lusutrombopag) in the UK for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures.
FDA grants Avatrombopag Orphan Drug Designation for thrombocytopenia europeanpharmaceuticalreview
January 15, 2020
The US FDA has granted avatrombopag (Doptelet) ODD as around 10 percent of US cancer patients per year experience chemotherapy-induced thrombocytopenia (CIT) with no available treatment.
FDA approves Shionogi’s Mulpleta for CLD-associated thrombocytopenia pharmaceutical-technology
August 06, 2018
The US Food and Drug Administration (FDA) has approved Japanese pharmaceutical company Shionogi’s drug Mulpleta (lusutrombopag) indicated for thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo a medical procedure.
FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease drugs
August 01, 2018
The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
Rigel bags first FDA approval pharmatimes
July 16, 2018
Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.
Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia biospace
April 10, 2018
FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB: PRTX)today announced that the Company has enrolled the first of three patients in cohort four of its U.S./U.K.